Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab ( (GMAB) ) has issued an announcement.
On June 17, 2025, Genmab A/S announced a capital increase of 32,117 shares due to the exercise of employee warrants, raising approximately DKK 33.3 million. The new shares, which represent about 0.05% of the company’s share capital, will be listed on Nasdaq Copenhagen and provide rights to dividends. This move reflects Genmab’s ongoing efforts to incentivize employees and strengthen its financial position, potentially enhancing its market competitiveness.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score is driven primarily by its strong financial performance, with a robust balance sheet and effective cash flow management. The technical analysis also supports a positive outlook, although the stock may be nearing overbought levels. Valuation metrics are favorable, though the lack of a dividend yield is a minor drawback.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, Genmab has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. The company aims to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 1,415,977
Technical Sentiment Signal: Sell
Current Market Cap: $14.04B
See more data about GMAB stock on TipRanks’ Stock Analysis page.